Stock OTLK OUTLOOK THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Outlook Therapeutics, Inc.

Equities

OTLK

US69012T3059

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-15 pm EDT 		5-day change 1st Jan Change
8.62 USD -0.92% Intraday chart for Outlook Therapeutics, Inc. -7.81% +9.39%
Mar. 28 North American Morning Briefing : Stocks Set for -2- DJ
Mar. 27 Outlook Therapeutics Shares Rise After BTIG Upgrade MT

Evolution of the average Target Price on Outlook Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

7cf9c98.piK-Z_s4Nabu5hTVvYaGdn1zEHLoWmKrS-UFMXGmnas.wxT2HrpVcMfaiGa6jfKrHgxGZUe7MRTfI5NLVRvv5fHuVNxVvXxx7ZSJRQ~b528f4f773e8a566ea692506496c21f7

Analyst Recommendations on Outlook Therapeutics, Inc.

BTIG Upgrades Outlook Therapeutics to Buy From Neutral, Price Target at $50 MT
Chardan Upgrades Outlook Therapeutics to Buy From Neutral, $3 Price Target; Says Risk/Reward is Favorable for Lytenava BLA Resubmission MT
Chardan Upgrades Outlook Therapeutics to Buy From Neutral, $3 Price Target MT
Guggenheim Upgrades Outlook Therapeutics to Buy From Neutral, Sets Price Target at $2 MT
Brookline Capital Upgrades Outlook Therapeutics to Buy From Hold, Price Target is $1.57 MT
Capital One Upgrades Outlook Therapeutics to Overweight From Equalweight With $5 Price Target MT
Chardan Downgrades Outlook Therapeutics to Neutral From Buy MT
HC Wainwright Downgrades Outlook Therapeutics to Neutral From Buy, Price Target is $1 MT
Brookline Capital Downgrades Outlook Therapeutics to Hold From Buy MT
Cantor Fitzgerald Downgrades Outlook Therapeutics to Neutral From Overweight, Adjusts Price Target to $1 From $4.50 MT
BTIG Downgrades Outlook Therapeutics to Neutral From Buy MT
Capital One Initiates Outlook Therapeutics With Overweight Rating, $5 Price Target MT
Guggenheim Initiates Outlook Therapeutics at Buy With $5 Price Target MT
Cantor Fitzgerald Initiates Outlook Therapeutics at Overweight With $4 Price Target MT
HC Wainwright Adjusts Price Target on Outlook Therapeutics to $5 From $6, Maintains Buy Rating MT
BTIG Starts Outlook Therapeutics at Buy With $7 Price Target MT
Chardan Capital Starts Outlook Therapeutics at Buy With $10 Price Target MT
Ascendiant Capital Adjusts Price Target on Outlook Therapeutics to $7.25 From $7, Maintains Buy Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
8.7 USD
Average target price
39.86 USD
Spread / Average Target
+358.13%
High Price Target
60 USD
Spread / Highest target
+589.66%
Low Price Target
25 USD
Spread / Lowest Target
+187.36%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Outlook Therapeutics, Inc.

BTIG
Chardan Research
Guggenheim
Brookline Capital Markets
Capital One Securities
HC Wainwright
Cantor Fitzgerald
Ascendiant Capital

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. OTLK Stock
  4. Consensus Outlook Therapeutics, Inc.